Drug Addiction and Autoimmune Disorders: Effects of Methylcobalamin on Both Conditions

Overview

This study used Danio rerio embryos to investigate the association between drug addiction and autoimmune disorders, as well as the eï¬€ects of an immune-boosting antioxidant, Methylcobalamin, on both conditions. Autoimmune conditions and substance abuse disorders are on the rise globally. The numbers in the US alone in 2023 stand at a staggering 20.4 million diagnosed with addictions and over 50 million affected with some kind of an autoimmune disorder. The United States spends over $35 billion annually to treat substance disorders, and another $100 billion on autoimmune disorders. A compromised immune system lies at the core of both conditions, yet few attempts have been made to establish an association between them. The results showed that the antioxidant groups performed better than the non-antioxidant groups in all of the assays. However, the nicotine and lupus groups were not closely matched across assays, suggesting that the eï¬€ects may be specific to the exact conditions tested, nicotine addiction and lupus, not addiction and autoimmune disorders broadly. The findings suggest that Methylcobalamin could be an eï¬€ective treatment for nicotine addiction and lupus. The study also emphasizes the importance of exploring the potential of antioxidants in treating other autoimmune disorders and identifying specific nutritional deficiencies caused by substance abuse that lead to autoimmune conditions. Overall, this research provides valuable insights into the relationship between drug addiction and autoimmune disorders and that if the Danio rerio model is applicable to humans, antioxidants like Methylcobalamin, can be extremely effective and affordable treatment options to treat both disorder